Acute ischemic stroke (AIS) is defined as the sudden loss of blood flow to an area of the brain with the consequent loss of neurological function. It is caused due to thrombotic or embolic occlusion of a cerebral artery and is more common than hemorrhagic stroke. Symptoms depend on the severity of the stroke and its location in the brain. Few people have no symptoms while Online Pharmacies only have one of the numerous symptoms. However, most people experience a combination of symptoms such as paralysis on one side of the body, changes in alertness, and changes in hearing or taste, difficulty in swallowing, dizziness or loss of balance, visual disturbances, and others.
Market Dynamics
Tobacco smoking is one of the major cause of cardiovascular disease, such as coronary heart disease, high blood pressure, heart attack, stroke, and Online Pharmacies. When a person smokes a cigarette, the blood that is distributed to the rest of the body becomes contaminated with chemicals in the smoke. These chemicals can damage the heart and blood vessels, which can lead to cardiovascular disease (CVD), the leading cause of death in the U.S. For instance, key facts provided by World Health Organization (WHO) in 2021, tobacco kills more than eight million people each year, globally. More than seven million of these deaths are due to direct tobacco use, while about 1.2 million are due to non-smokers exposed to secondhand smoke (combination of smoke from the burning end of a cigarette and the smoke breathed out by smokers). More than 80% of the world's 1.3 billion tobacco users live in low- and middle-income countries such as Bangladesh, India, Afghanistan, and Online Pharmacies.
Key features of the study:
- This report provides in-depth analysis of the global acute ischemic stroke (AIS) market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global acute ischemic stroke (AIS) market based on the following parameters – company highlights, types portfolio, key highlights, financial performance, and market strategies
- Key companies covered as a part of this study include F. Hoffmann-La Roche AG, Boehringer Ingelheim, Bayer AG, Pfizer Inc., Biogen, Daiichi Sankyo, Bristol-Myers Squibb, Johnson & Johnson, AstraZeneca, SanBio and Athersys Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global acute ischemic stroke (AIS) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute ischemic stroke (AIS) market
Detailed Segmentation:
- Global Acute Ischemic Stroke (AIS) Market, By Therapeutics:
- Tissue Plasminogen Activator
- Anticoagulant
- Antiplatelet
- Antihypertensive
- Global Acute Ischemic Stroke (AIS) Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Acute Ischemic Stroke (AIS) Market, By Region:
- North America
- By Therapeutics
- Tissue Plasminogen Activator
- Anticoagulant
- Antiplatelet
- Antihypertensive
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Latin America
- By Therapeutics
- Tissue Plasminogen Activator
- Anticoagulant
- Antiplatelet
- Antihypertensive
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Therapeutics
- Tissue Plasminogen Activator
- Anticoagulant
- Antiplatelet
- Antihypertensive
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Therapeutics
- Tissue Plasminogen Activator
- Anticoagulant
- Antiplatelet
- Antihypertensive
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Therapeutics
- Tissue Plasminogen Activator
- Anticoagulant
- Antiplatelet
- Antihypertensive
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Therapeutics
- Tissue Plasminogen Activator
- Anticoagulant
- Antiplatelet
- Antihypertensive
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region/Country
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Hoffmann-La Roche AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Boehringer Ingelheim
- Bayer AG
- Pfizer Inc.
- Biogen
- Daiichi Sankyo
- Bristol-Myers Squibb
- Johnson & Johnson
- AstraZeneca
- SanBio
- Athersys Inc.
“*” marked represents similar segmentation in other categories in the respective section.
